3M (MMM) Q3 2025 earnings summary

Executive summary

• Q3 2025 delivered organic sales growth of 3.2%–3.5%, with adjusted sales of $6.3B and GAAP sales of $6.5B, marking the fourth consecutive quarter of positive growth across all business groups despite a soft macro environment.

• Adjusted EPS rose 10% year-over-year to $2.19, while GAAP EPS declined 38% to $1.55 due to special items including litigation and divestiture costs.

• Free cash flow reached $1.3B in Q3 with 111% conversion, and $0.9B was returned to shareholders via dividends and buybacks.

• Commercial excellence and new product introductions drove performance, with 70 new products launched in Q3 and 196 year-to-date.

• The company completed the spin-off of its Health Care business (Solventum) in April 2024, now reported as discontinued operations.

Financial highlights

• Q3 organic revenue growth was 3.2%–3.5% year-over-year, with adjusted operating margin at 24.7% (up 170 bps YoY) and GAAP operating margin at 22.2%.

• Adjusted EPS for Q3 was $2.19 (up 10% YoY); for the nine months, adjusted EPS was $6.23 (up 11%).

• Operating income grew by $175M in constant currency, with $325M from volume growth and productivity.

• Cash flow from operating activities increased by $0.7B YoY, driven by lower litigation payments.

• Dividends paid totaled $2.19 per share for the first nine months.

Outlook and guidance

• Full-year 2025 adjusted EPS guidance raised to $7.95–$8.05, with organic sales growth expected above 2% and adjusted operating margin expansion of 180–200 bps.

• Free cash flow conversion expected to remain above 100%.

• Capital spending for 2025 is expected to be approximately $0.9B, focused on growth, productivity, and sustainability.

• The company is progressing toward exiting all PFAS manufacturing by the end of 2025, with ongoing cost dis-synergies expected.

• 2026 framework targets growth above macro, continued margin expansion, and strong free cash flow.